Hansa Biopharma Reports the Results from the NICE-01 Clinical Evaluation of HNSA-5487
Shots:
- Hansa Biopharma has reported 12mos. follow-up results from NICE-01 study assessing safety, tolerability & PK/PD of HNSA-5487’s (IV) single ascending doses among healthy subjects (n=36)
- Study showed >95% reduction in IgG levels within few hours that restored to normal after 6mos. & decreased the levels of pre-treatment anti-drug antibody (ADA), suggesting its favorable immunogenicity. HNSA-5487 was effective in nearly 100% of samples, without any SAEs
- The company will now advance HNSA-5487 in chronic autoimmune diseases incl. myelin oligodendrocyte glycoprotein antibody disease (MOGAD), neuromyelitis optica (NMO) & myasthenia gravis (MG)
Ref: Hansa Biopharma | Image: Hansa Biopharma
Related News:- Hansa Biopharma Reports First Patient Treatment of Imlifidase in P-II Study for ANCA-Associated Vasculitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
